Literature DB >> 12091419

Relationship between electrophysiological, psychophysical, and anatomical measurements in glaucoma.

David F Garway-Heath1, Graham E Holder, Fred W Fitzke, Roger A Hitchings.   

Abstract

PURPOSE: To evaluate the relationship between electrophysiological, psychophysical, and structural measurements in normal and glaucomatous eyes and to test the hypothesis that there is a continuous structure-function relationship between ganglion cell numbers and visual field sensitivity.
METHODS: Thirty-four normal subjects and 40 patients with glaucoma were examined with the pattern electroretinogram (PERG), perimetry and retinal tomography. Transient and steady state (SS) PERGs were recorded, and peak (P)-to-trough (N) amplitude was measured. The unit of differential light sensitivity (DLS) in perimetry is the decibel. The decibel is 10. log(1/Lambert), where the Lambert is the unit of test spot intensity. PERG amplitudes were correlated with decibel and 1/Lambert DLS for the central 18 degrees of the visual field and with neuroretinal rim area in the temporal part of the optic disc. Age-related changes in the structural and functional measurements were sought. The correlation between variables was investigated by linear and quadratic regression analysis. A quadratic (y = ax + bx(2) + c) fit was taken to be significantly better than a linear fit, if the coefficient (b) for the x(2) term was significant at P < 0.05.
RESULTS: A quadratic fit between decibel DLS and PERG amplitude (transient PERG: R(2) = 0.40, P = 0.0000; SS PERG: R(2) = 0.32, P = 0.0000) was significantly better than a linear fit. There was a linear correlation between 1/Lambert DLS and PERG amplitude (transient PERG: R(2) = 0.44, P = 0.0000; SS PERG: R(2) = 0.35, P = 0.0000). There was a linear correlation between temporal neuroretinal rim area and PERG amplitude (transient PERG: R(2) = 0.17, P = 0.0003; SS PERG: R(2) = 0.20, P = 0.0001). A quadratic fit between decibel DLS and temporal neuroretinal rim area (R(2) = 0.38, P = 0.0000) was significantly better than a linear fit. There was a linear correlation between 1/Lambert DLS and temporal neuroretinal rim area (R(2) = 0.30, P = 0.0000). Both DLS and PERG amplitude declined with age in the normal subjects. The rate of decline was -0.17%, -0.74%, -0.75%, and -0.78% per year for decibel DLS, 1/Lambert DLS, transient PERG, and SS PERG, respectively.
CONCLUSIONS: There is a curvilinear relationship between decibel DLS and both PERG amplitude and neuroretinal rim area, and a linear relationship between 1/Lambert DLS and PERG amplitude and neuroretinal rim area. These findings support the hypothesis that there is no ganglion cell functional reserve but a continuous structure-function relationship, and that the impression of a functional reserve results from the logarithmic (decibel) scaling of the visual field.

Entities:  

Mesh:

Year:  2002        PMID: 12091419

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  95 in total

1.  Different effect of dioptric defocus vs. light scatter on the pattern electroretinogram (PERG).

Authors:  Michael Bach; Marcel Mathieu
Journal:  Doc Ophthalmol       Date:  2004-01       Impact factor: 2.379

2.  Relationships between visual field sensitivity and spectral absorption properties of the neuroretinal rim in glaucoma by multispectral imaging.

Authors:  Jonathan Denniss; Ingo Schiessl; Vincent Nourrit; Cecilia H Fenerty; Ramesh Gautam; David B Henson
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-07       Impact factor: 4.799

3.  Retinal ganglion cell and inner plexiform layer thickness measurements in regions of severe visual field sensitivity loss in patients with glaucoma.

Authors:  A L de A Moura; A S Raza; M A Lazow; C G De Moraes; D C Hood
Journal:  Eye (Lond)       Date:  2012-06-15       Impact factor: 3.775

4.  Frequency-doubling technology and retinal measurements with spectral-domain optical coherence tomography in preperimetric glaucoma.

Authors:  Takafumi Hirashima; Masanori Hangai; Masayuki Nukada; Noriko Nakano; Satoshi Morooka; Tadamichi Akagi; Atsushi Nonaka; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-06-12       Impact factor: 3.117

5.  Structure-function relationships using the Cirrus spectral domain optical coherence tomograph and standard automated perimetry.

Authors:  Mauro T Leite; Linda M Zangwill; Robert N Weinreb; Harsha L Rao; Luciana M Alencar; Felipe A Medeiros
Journal:  J Glaucoma       Date:  2012-01       Impact factor: 2.503

6.  Pattern electroretinogram association with spectral domain-OCT structural measurements in glaucoma.

Authors:  C Bowd; A Tafreshi; L M Zangwill; F A Medeiros; P A Sample; R N Weinreb
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

7.  Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5'-diphosphocholine (citicoline): a study of 8 years of follow-up.

Authors:  Vincenzo Parisi
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

8.  Results of the betaxolol versus placebo treatment trial in ocular hypertension.

Authors:  Deborah Kamal; David Garway-Heath; Simon Ruben; Fiona O'Sullivan; Catey Bunce; Anath Viswanathan; Wendy Franks; Roger Hitchings
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-19       Impact factor: 3.117

9.  Ganglion cell loss in early glaucoma, as assessed by photopic negative response, pattern electroretinogram, and spectral-domain optical coherence tomography.

Authors:  Barbara Cvenkel; Maja Sustar; Darko Perovšek
Journal:  Doc Ophthalmol       Date:  2017-05-31       Impact factor: 2.379

10.  Retinal nerve fiber structure versus visual field function in patients with ischemic optic neuropathy. A test of a linear model.

Authors:  Donald C Hood; Susan Anderson; Jacinthe Rouleau; Adam S Wenick; Larissa K Grover; Myles M Behrens; Jeffrey G Odel; Andrew G Lee; Randy H Kardon
Journal:  Ophthalmology       Date:  2007-09-17       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.